Updated on 21 February 2013
Tetravalent DPT-IPV vaccine combines Kitasato Daiichi Sankyo DPT vaccine and Sanofi Pasteur enhanced inactivated Salk poliomyelitis vaccine
Singapore: Kitasato Daiichi Sankyo, a member of the Daiichi Sankyo Group, has applied for approval of its tetravalent combination DPT-IPV vaccine in Japan for the prevention of diphtheria, pertussis (whooping cough), tetanus, and acute poliomyelitis (polio).
DPT-IPV vaccine, which is supplied in pre-filled syringes, combines DPT vaccine from Kitasato Daiichi Sankyo and the enhanced inactivated Salk poliomyelitis vaccine (eIPV) from Sanofi Pasteur.
The Daiichi Sankyo Group and Sanofi Pasteur contribute to the protection and improvement of people's health and hygiene and the enhancement and dissemination of preventive medicine in Japan by supplying vaccines that meet unmet medical needs.